• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


| Print

Puma Biotechnology (PBYI)

Common Shares
Sell: $5.60|Buy: $6.24|Change: 0.03 (-0.49%)

This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP

Company profile

Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.

Address

10880 Wilshire Boulevard
Suite 2150
Los Angeles
CA
USA
90024

Telephone

+1 212 8454271

Website

https://www.pumabiotechnology.com

Sector 

Healthcare

Forecast key dates

NameKey Date
Puma Biotechnology Inc Fourth Quarter Earnings Conference Call for 20262027-02-26T16:30:00
Puma Biotechnology Inc Fourth Quarter Earnings Results for 20262027-02-26T00:00:00
Puma Biotechnology Inc Annual Report for 20262027-02-26T00:00:00
Puma Biotechnology Inc Third Quarter Earnings Conference Call for 20262026-11-06T16:30:00
Puma Biotechnology Inc Third Quarter Earnings Results for 20262026-11-06T00:00:00
Puma Biotechnology Inc Second Quarter Earnings Conference Call for 20262026-08-07T16:30:00
Puma Biotechnology Inc Second Quarter Earnings Results for 20262026-08-07T00:00:00
Puma Biotechnology Inc Annual General Meeting for 20262026-06-11T13:00:00
Puma Biotechnology Inc First Quarter Earnings Conference Call for 20262026-05-08T16:30:00
Puma Biotechnology Inc First Quarter Earnings Results for 20262026-05-08T00:00:00
TD Cowen 46th Annual Health Care Conference2026-03-02T14:30:00

Previous key dates

NameKey Date
TD Cowen 46th Annual Health Care Conference2026-03-02T14:30:00
Puma Biotechnology Inc Fourth Quarter Earnings Conference Call for 20252026-02-26T16:30:00
Puma Biotechnology Inc Fourth Quarter Earnings Results for 20252026-02-26T00:00:00
Puma Biotechnology Inc Annual Report for 20252026-02-26T00:00:00
Puma Biotechnology Inc Third Quarter Earnings Conference Call for 20252025-11-06T16:30:00
Puma Biotechnology Inc Third Quarter Earnings Result for 20252025-11-06T00:00:00
H.C. Wainwright 27th Annual Global Investment Conference2025-09-08T13:00:00
Puma Biotechnology Inc Second Quarter Earnings Conference Call for 20252025-08-07T16:30:00
Puma Biotechnology Inc Second Quarter Earnings Results for 20252025-08-07T00:00:00
Puma Biotechnology Inc Annual General Meeting for 20252025-06-11T13:00:00
Puma Biotechnology Inc First Quarter Earnings Conference Call for 20252025-05-08T16:30:00
Puma Biotechnology Inc First Quarter Earnings Result for 20252025-05-08T00:00:00
Barclays Annual Global Healthcare Conference2025-03-11T14:00:00
TD Cowen’s 45th Annual Health Care Conference2025-03-05T11:10:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2026 AJ Bell. All rights reserved.